

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1-71. (Cancelled)

72.(New) A powdered pharmaceutical composition comprising the serine protease inhibitor alpha I-antitrypsin (AAT), trehalose, polysorbate 80 and methionine, wherein the AAT, the trehalose, the polysorbate 80 and the methionine are present in amounts such that if the powder is solubilized in a liquid pharmaceutical composition for administration to a patient, the AAT concentration is about 50 mg/ml, the trehalose concentration is about 25 mg/ml, the polysorbate 80 concentration is about 0.1 or about 0.02% (w/v), and the methionine concentration is about 5 mM.

73.(new) A liquid pharmaceutical composition comprising the serine protease inhibitor alpha I-antitrypsin (AAT), trehalose, polysorbate 80 and methionine, wherein the AAT concentration is about 50 mg/ml, the trehalose concentration is about 25 mg/ml, the polysorbate 80 concentration is about 0.1 or about 0.02% (w/v), and the methionine concentration is about 5 mM.

74.(New) The composition of claim 72 or 73, wherein the AAT is a recombinant AAT.

75. (New) The composition of claim 72 or 73, wherein the AAT is glycosylated.

76.(New) The composition of claim 72 or 73, wherein the AAT is unglycosylated.

77.(New) The composition of claim 72 or 73, wherein the liquid pharmaceutical composition further comprises 10mM sodium phosphate buffer pH 7.4.